Cargando…

Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment

BACKGROUND: Decrease in estimated glomerular filtration rate (eGFR) during Tenofovir disoproxil fumarate (TDF) treatment remains a concern, and few patients experience partial recovery of eGFR. This study aimed to investigate the risk factors for eGFR recovery in patients with and without hypertrigl...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Ya-ru, Liu, Si-qi, He, Yi-shan, Xue, Yuan, Wang, Jian, Huang, Rui, Wu, Chao, Lu, Jian-chun, Liu, Long-gen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979984/
https://www.ncbi.nlm.nih.gov/pubmed/36856541
http://dx.doi.org/10.1080/07853890.2023.2177725
_version_ 1784899829458010112
author Pan, Ya-ru
Liu, Si-qi
He, Yi-shan
Xue, Yuan
Wang, Jian
Huang, Rui
Wu, Chao
Lu, Jian-chun
Liu, Long-gen
author_facet Pan, Ya-ru
Liu, Si-qi
He, Yi-shan
Xue, Yuan
Wang, Jian
Huang, Rui
Wu, Chao
Lu, Jian-chun
Liu, Long-gen
author_sort Pan, Ya-ru
collection PubMed
description BACKGROUND: Decrease in estimated glomerular filtration rate (eGFR) during Tenofovir disoproxil fumarate (TDF) treatment remains a concern, and few patients experience partial recovery of eGFR. This study aimed to investigate the risk factors for eGFR recovery in patients with and without hypertriglyceridemia. METHODS: A total of 203 patients with chronic HBV infection were prospectively recruited and followed up for three years. Data were collected at baseline, first, second, and third years during TDF treatment. RESULTS: Most patients achieved normal ALT (80.0% vs. 82.5%) and undetectable HBV DNA (95.0% vs. 95.6%) in both groups (p > 0.05). For patients with hypertriglyceridemia, eGFR and cholesterol did not change significantly during the 3-year follow-up, while triglyceride (TG) decreased significantly in the first year and persisted at a lower level in the subsequent two years. For patients without hypertriglyceridemia, eGFR declined significantly in the first year of treatment, then gradually recovered during the subsequent two years, and eGFR was negatively correlated with TG at the four time points. Fifteen (15/183, 8.2%) patients without hypertriglyceridemia experienced eGFR partial recovery in the third year. Univariate and multivariate analyses showed that baseline eGFR <90 mL/(min·1.73 m(2)) (p < 0.01; 95% CI: 0.019–0.284) and age (p < 0.01; 95% CI: 0.817–0.960) were independent risk factors for eGFR recovery. CONCLUSION: eGFR partially recovered in patients without hypertriglyceridemia during TDF treatment, and TG regulation might be a useful strategy to hinder renal function decline, although larger, confirmatory studies are necessary to validate our findings. KEY MESSAGES: For patients with normal triglyceride, eGFR declined significantly at the first year of TDF treatment, then gradually recovered during the subsequent two years, and eGFR was negatively correlated with TG. Baseline eGFR <90 mL/(min·1.73 m(2)) and age were independent risk factors for eGFR recovery.
format Online
Article
Text
id pubmed-9979984
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-99799842023-03-03 Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment Pan, Ya-ru Liu, Si-qi He, Yi-shan Xue, Yuan Wang, Jian Huang, Rui Wu, Chao Lu, Jian-chun Liu, Long-gen Ann Med Original Article BACKGROUND: Decrease in estimated glomerular filtration rate (eGFR) during Tenofovir disoproxil fumarate (TDF) treatment remains a concern, and few patients experience partial recovery of eGFR. This study aimed to investigate the risk factors for eGFR recovery in patients with and without hypertriglyceridemia. METHODS: A total of 203 patients with chronic HBV infection were prospectively recruited and followed up for three years. Data were collected at baseline, first, second, and third years during TDF treatment. RESULTS: Most patients achieved normal ALT (80.0% vs. 82.5%) and undetectable HBV DNA (95.0% vs. 95.6%) in both groups (p > 0.05). For patients with hypertriglyceridemia, eGFR and cholesterol did not change significantly during the 3-year follow-up, while triglyceride (TG) decreased significantly in the first year and persisted at a lower level in the subsequent two years. For patients without hypertriglyceridemia, eGFR declined significantly in the first year of treatment, then gradually recovered during the subsequent two years, and eGFR was negatively correlated with TG at the four time points. Fifteen (15/183, 8.2%) patients without hypertriglyceridemia experienced eGFR partial recovery in the third year. Univariate and multivariate analyses showed that baseline eGFR <90 mL/(min·1.73 m(2)) (p < 0.01; 95% CI: 0.019–0.284) and age (p < 0.01; 95% CI: 0.817–0.960) were independent risk factors for eGFR recovery. CONCLUSION: eGFR partially recovered in patients without hypertriglyceridemia during TDF treatment, and TG regulation might be a useful strategy to hinder renal function decline, although larger, confirmatory studies are necessary to validate our findings. KEY MESSAGES: For patients with normal triglyceride, eGFR declined significantly at the first year of TDF treatment, then gradually recovered during the subsequent two years, and eGFR was negatively correlated with TG. Baseline eGFR <90 mL/(min·1.73 m(2)) and age were independent risk factors for eGFR recovery. Taylor & Francis 2023-03-01 /pmc/articles/PMC9979984/ /pubmed/36856541 http://dx.doi.org/10.1080/07853890.2023.2177725 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Pan, Ya-ru
Liu, Si-qi
He, Yi-shan
Xue, Yuan
Wang, Jian
Huang, Rui
Wu, Chao
Lu, Jian-chun
Liu, Long-gen
Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment
title Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment
title_full Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment
title_fullStr Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment
title_full_unstemmed Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment
title_short Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment
title_sort estimated glomerular filtration rate partially recovered in patients without hypertriglyceridemia during tenofovir disoproxil fumarate treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979984/
https://www.ncbi.nlm.nih.gov/pubmed/36856541
http://dx.doi.org/10.1080/07853890.2023.2177725
work_keys_str_mv AT panyaru estimatedglomerularfiltrationratepartiallyrecoveredinpatientswithouthypertriglyceridemiaduringtenofovirdisoproxilfumaratetreatment
AT liusiqi estimatedglomerularfiltrationratepartiallyrecoveredinpatientswithouthypertriglyceridemiaduringtenofovirdisoproxilfumaratetreatment
AT heyishan estimatedglomerularfiltrationratepartiallyrecoveredinpatientswithouthypertriglyceridemiaduringtenofovirdisoproxilfumaratetreatment
AT xueyuan estimatedglomerularfiltrationratepartiallyrecoveredinpatientswithouthypertriglyceridemiaduringtenofovirdisoproxilfumaratetreatment
AT wangjian estimatedglomerularfiltrationratepartiallyrecoveredinpatientswithouthypertriglyceridemiaduringtenofovirdisoproxilfumaratetreatment
AT huangrui estimatedglomerularfiltrationratepartiallyrecoveredinpatientswithouthypertriglyceridemiaduringtenofovirdisoproxilfumaratetreatment
AT wuchao estimatedglomerularfiltrationratepartiallyrecoveredinpatientswithouthypertriglyceridemiaduringtenofovirdisoproxilfumaratetreatment
AT lujianchun estimatedglomerularfiltrationratepartiallyrecoveredinpatientswithouthypertriglyceridemiaduringtenofovirdisoproxilfumaratetreatment
AT liulonggen estimatedglomerularfiltrationratepartiallyrecoveredinpatientswithouthypertriglyceridemiaduringtenofovirdisoproxilfumaratetreatment